Can targeted radiation boost lung cancer treatment? 4000-patient study seeks answers.
NCT ID NCT06613633
First seen Apr 30, 2026 · Last updated Jun 16, 2026 · Updated 6 times
Summary
This study looked at 4000 people with advanced lung cancer who had a specific gene mutation (EGFR) and were taking a targeted pill. The goal was to find the best time to add focused radiation to shrink any remaining tumors. Researchers tracked when tumors shrank the most and where they were located, to see if adding radiation is a good next step.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200050, China
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
-
Wuhan Tongji Hospital
Wuhan, Hubei, 430030, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.